|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0010583,
umls-concept:C0013089,
umls-concept:C0030705,
umls-concept:C0032952,
umls-concept:C0034656,
umls-concept:C0042679,
umls-concept:C0079731,
umls-concept:C0086960,
umls-concept:C0205390,
umls-concept:C0393022,
umls-concept:C0600688,
umls-concept:C1176309,
umls-concept:C1257890,
umls-concept:C1332206,
umls-concept:C1554217,
umls-concept:C1556084,
umls-concept:C2603343
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2009-9-23
|
|
pubmed:abstractText |
Bortezomib demonstrated promising activity in lymphomas. The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with the addition of bortezomib in patients with B-cell lymphoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD20,
http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/bortezomib,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
2009 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4540-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19593797-Adult,
pubmed-meshheading:19593797-Aged,
pubmed-meshheading:19593797-Antibodies, Monoclonal,
pubmed-meshheading:19593797-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19593797-Antigens, CD20,
pubmed-meshheading:19593797-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19593797-Boronic Acids,
pubmed-meshheading:19593797-Cyclophosphamide,
pubmed-meshheading:19593797-Doxorubicin,
pubmed-meshheading:19593797-Drug Administration Schedule,
pubmed-meshheading:19593797-Female,
pubmed-meshheading:19593797-Humans,
pubmed-meshheading:19593797-Lymphoma, B-Cell,
pubmed-meshheading:19593797-Male,
pubmed-meshheading:19593797-Middle Aged,
pubmed-meshheading:19593797-Prednisone,
pubmed-meshheading:19593797-Pyrazines,
pubmed-meshheading:19593797-Vincristine
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
|
|
pubmed:affiliation |
Hematology Department, Gustave Roussy Institute, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
